Related Experiment Videos
Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy
Ulrich Matzner1, Eva Herbst, Kerstin Khalaj Hedayati
1Institut Für Physiologische Chemi, Rheinische Friedrich-Wilhelms Universität, Nussallee 11, 53115 Bonn, Germany. matzner@institut.physiochem.uni-bonn.de
Human Molecular Genetics
|March 18, 2005
Summary
Enzyme replacement therapy (ERT) using arylsulfatase A (ASA) effectively reduced sulfatide accumulation in metachromatic leukodystrophy mouse models. This therapy showed promise for treating this devastating neurological disorder.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Arylsulfatase A (ASA) deficiency causes metachromatic leukodystrophy (MLD), a fatal lysosomal storage disease.
- MLD is characterized by toxic sphingolipid (sulfatide) accumulation, leading to demyelination and severe neurological impairment.
- Current treatments for MLD are limited, with no curative options available.
Purpose of the Study:
- To evaluate the therapeutic potential of enzyme replacement therapy (ERT) for MLD.
- To assess the efficacy of recombinant human ASA in reducing sulfatide storage in a mouse model of MLD.
Main Methods:
- ASA knockout mice received intravenous injections of recombinant human ASA.
- Sulfatide levels, enzyme pharmacokinetics, and tissue distribution were analyzed.
- Neurological function and histopathology were assessed post-treatment.
Main Results:
- Injected ASA showed rapid distribution but limited brain uptake initially.
- Single injections reduced sulfatide in peripheral tissues by up to 70%.
- Repeated injections effectively reduced sulfatide in the brain and spinal cord, improving histopathology and neurological function.
Conclusions:
- ERT with recombinant human ASA demonstrates significant therapeutic potential for MLD.
- The treatment ameliorated key disease pathologies and improved neurological outcomes in a preclinical model.
- Enzyme replacement therapy offers a promising strategy for managing this severe lysosomal storage disease.